Exact Sciences IPO
Exact Sciences is a molecular diagnostics company best known for developing Cologuard, a non-invasive colorectal cancer screening test. The company has expanded into other cancer screening and diagnostic areas through acquisitions and internal development. Investors follow the company due to its strong market position in cancer screening and potential for growth in precision medicine.
Key Facts
| Industry | Cancer Screening & Diagnostics |
| Founded | 1995 |
| Headquarters | Madison, WI |
| Employees | ~6,200 |
| Website | exactsciences.com |
| Funding | Public company (NASDAQ: EXAS) since 2001 |
About Exact Sciences
Exact Sciences is a leading molecular diagnostics company best known for developing Cologuard, a non-invasive stool-based DNA test for colorectal cancer screening that has revolutionized colon cancer detection. The FDA-approved test can detect colorectal cancer and precancerous lesions by analyzing DNA mutations and blood traces in stool samples, providing an alternative to traditional colonoscopy screening.
Since Cologuard's launch, the company has expanded its portfolio through acquisitions and internal development to include liquid biopsy tests for multiple cancer types, including Oncoguard (liver cancer screening) and tests for recurrence monitoring. Exact Sciences has also acquired Genomic Health (Oncotype DX breast cancer tests) and is developing multi-cancer early detection blood tests. The company has fundamentally changed cancer screening by making it more accessible and patient-friendly, with Cologuard now used by millions of patients and recommended by major medical guidelines.
IPO Status
Exact Sciences went public in February 2001 and trades on NASDAQ under the ticker symbol EXAS. The company's major breakthrough came with the FDA approval and commercialization of Cologuard, which transformed it from a development-stage company into a profitable diagnostics leader. The stock has experienced significant growth over the years, particularly following Cologuard's commercial success. Exact Sciences has made several strategic acquisitions to expand its capabilities in cancer diagnostics and has continued to invest in research and development for new screening technologies.
Competitors
Frequently Asked Questions
Does Exact Sciences have a stock?
Yes, Exact Sciences has been a public company since February 2001. The company trades on NASDAQ under the ticker symbol EXAS.
When is the Exact Sciences IPO date?
Exact Sciences completed its IPO over 20 years ago in February 2001. The company has been publicly traded since then.
How can I buy Exact Sciences stock?
You can purchase Exact Sciences stock through any brokerage account using the ticker symbol EXAS. The stock is listed on the NASDAQ exchange.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts